BeOne Medicines (ONC) Cash from Financing Activities (2015 - 2026)

BeOne Medicines (ONC) has reported Cash from Financing Activities for 12 consecutive years, with $68.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 303.19% year-over-year to $68.6 million; the TTM figure through Mar 2026 stood at $1.2 billion (up 44428.88% YoY), while the FY2025 annual figure was $1.1 billion, up 447.66% from the prior year.
• Cash from Financing Activities fell to $68.6 million in Q1 2026 per ONC's latest filing, from $96.9 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $961.3 million in Q3 2025 and bottomed at -$110.4 million in Q4 2022.
• Historically, Cash from Financing Activities has averaged $101.1 million across 5 years, with a median of $23.0 million in 2024.
• Annual changes were most pronounced in 2023 — Cash from Financing Activities tumbled 163.86% — and 2025, when it surged 7491.79%.
• BeOne Medicines' Cash from Financing Activities stood at -$110.4 million in 2022, then soared by 414.45% to $347.0 million in 2023, then tumbled by 101.3% to -$4.5 million in 2024, then jumped by 2243.07% to $96.9 million in 2025, then dropped by 29.19% to $68.6 million in 2026.
• Business Quant data shows ONC's Cash from Financing Activities at $68.6 million in Q1 2026, $96.9 million in Q4 2025, and $961.3 million in Q3 2025.